Werewolf Therapeutics, Inc.
Clinical trials sponsored by Werewolf Therapeutics, Inc., explained in plain language.
-
New cancer drug enters first human trials for Tough-to-Treat tumors
Disease control OngoingThis is a first-in-human study to test the safety and early effectiveness of a new drug called WTX-124, given alone and in combination with an existing immunotherapy (pembrolizumab). It will enroll about 150 adults with advanced or metastatic solid tumors, such as melanoma or kid…
Phase: PHASE1 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New cancer drug seeks right dose to fight tough tumors
Disease control OngoingThis early-stage trial is testing a new drug called WTX-330 in adults with advanced solid tumors or non-Hodgkin lymphoma that have stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see if the drug can shrink tumors. Re…
Phase: PHASE1, PHASE2 • Sponsor: Werewolf Therapeutics, Inc. • Aim: Disease control
Last updated Mar 06, 2026 15:38 UTC